该药为E-选择素抑制剂,以内皮细胞为靶点,阻断骨髓细胞与白血病髓样细胞的粘附。
在对 388 名复发/难治性急性髓系白血病 (AML) 患者进...查看全文
Glycomimetics(GLYC)05-07 04:05
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001558370-24-006793 Act: 34 Size: 7 MB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011861 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 20:35
$Glycomimetics(GLYC)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001558370-24-006459 Act: 34 Size: 320 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011872 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011867 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011862 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)06-04 21:35
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-008882 Act: 34 Size: 8 MB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011860 Size: 5 KB 网页链接查看全文
chuminhua2020-02-12 16:33
2/11, 2011年Pfizer$辉瑞(PFE)$ 与GlycoMimetics$Glycomimetics(GLYC)$ 达成授权许可协议,共同开发炎症抑制剂GMI-1070(Rivipansel)用于镰状细胞病治疗,交易价值3.4亿美元。但是现在,GlycoMimetics在SEC上发布文件称,2月5日该公司收到了Pfizer终止协议的书面通知,将在4月5日生效。协议终止后...查看全文
chuminhua2020-01-09 23:54
1/6,GlycoMimetics, Inc.$Glycomimetics(GLYC)$ 和Apollomics, Inc. (冠科美博)宣布就急性髓系白血病治疗药物Uproleselan和GMI-1687的中国市场独家开发和商业化权利签署合作许可协议。Uproleselan和GMI-1687是临床应用前景广泛的E-选择素拮抗剂,其中Uproleselan在美国已经进入III期临床试验,...查看全文
淘沙见金2019-08-05 19:21
药药!切克闹!下周视频来一套!本周视频分析内容如下:1.生物医药板块宏观大趋势 2.GLYC $Glycomimetics(GLYC)$ 更新
3. ADVM $Adverum生物科技(ADVM)$ - 为什么我们不看好ADVM-022基因疗法在wet AMD上的数据?4. 交易提醒-LPTX $Leap Therapeutics(LPTX)$ /AGRX
视频观看地址:网页链接查看全文
淘沙见金2019-07-24 22:05
$Glycomimetics(GLYC)$ 股价走势像是结果泄漏了,不过这是大药厂负责的临床应该没有那么容易泄密才对。Anyway, rivipansel之前二期的数据还是很solid的,虽然主要终点p值不够,但是trend很明显。这次三期人数X4,入组条件也比之前要宽松,个人认为辉瑞成功的概率超过50%. *个人观点,非投资意见。查看全文
淘沙见金2019-07-22 22:31
$Glycomimetics(GLYC)$ CEO Rachel King关于Rivipansel的评价,一副信心十足的感觉。当然,对于管理层的话需要take a grain of salt. 跟疼痛相关的临床结果实际上不好预测,所以只能小仓位赌一下。辉瑞5月初病人招募完成,理论上买8月16号的期权应该可以赶上这个催化剂。*个人观点,非投资建议。查看全文
Replix锐璞美股2019-07-08 07:21
本周视频分析已经上线,内容见附图。链接如下:网页链接 欢迎分享,请注明来源Replix锐璞美股即可。 $再生元制药(REGN)$ $阿玛琳(AMRN)$ $Glycomimetics(GLYC)$查看全文
$Glycomimetics(GLYC)$ 8-K Current report, item 3.01 Accession Number: 0001558370-24-009508 Act: 34 Size: 173 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017978 Size: 6 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017623 Size: 5 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, item 5.02 Accession Number: 0001558370-24-009140 Act: 34 Size: 182 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-008882 Act: 34 Size: 8 MB 网页链接
$Glycomimetics(GLYC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-007632 Act: 34 Size: 4 MB 网页链接
$Glycomimetics(GLYC)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001072613-24-000441 Act: 34 Size: 121 KB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001558370-24-006793 Act: 34 Size: 7 MB 网页链接
$Glycomimetics(GLYC)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001558370-24-006459 Act: 34 Size: 320 KB 网页链接
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011860 Size: 5 KB 网页链接